Serum exosomal microRNAs as predictive markers for EGFR mutations in non–small-cell lung cancer

• Main Authors: Dai, L. (Author), Luo, M. (Author), Wang, L. (Author), Xia, J. (Author), Zhu, J. (Author)
• Format: Article
• Language: English
• Published: John Wiley and Sons Inc 2021
• Subjects: adult; aged; Aged; Article; biology; Biomarkers, Tumor; blood; blood sampling; cancer patient; cancer staging; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computational Biology; controlled study; down regulation; early cancer; EGFR; EGFR gene; EGFR protein, human; epidermal growth factor receptor; ErbB Receptors; exosome; Exosomes; female; Female; gene expression; gene mutation; gene ontology; Gene Ontology; genetics; human; Humans; Lung Neoplasms; lung tumor; major clinical study; male; Male; microRNA; microRNA 1116; microRNA 1169; microRNA 117; microRNA 1214; microRNA 1228; microRNA 1384; microRNA 15b 5p; microRNA 260; microRNA 342 5p; microRNA 403; microRNA 56; microRNA 604; microRNA 689; microRNA 72; microRNA 731; microRNA 818; microRNA 836; microRNA 898; microRNA 955; microRNA 99b 5p; MicroRNAs; middle aged; Middle Aged; miRNAs; mutant; mutation; Mutation; non invasive procedure; non small cell lung cancer; NSCLC; prediction; reproducibility; Reproducibility of Results; RNA sequencing; tumor cell line; tumor derived exosome; tumor marker; ultrastructure; unclassified drug; upregulation; wild type
• Online Access: View Fulltext in Publisher

 Background: Current therapeutic drugs show positive effects on non–small-cell lung cancer (NSCLC) patients with mutant epidermal growth factor receptor (EGFR) expression, whereas a lesser beneficial effect is generally noted on NSCLC patients with wild-type EGFR. Therefore, identification of new detection methods for the accurate clinical diagnosis of NSCLC is essential. Methods: In this study, tumor-derived exosomes from the plasma of EGFR mutation and wild-type NSCLC patients were isolated. Extensive exosomal miRNA profiling of EGFR mutation and wild-type NSCLC patients, in comparison with healthy individuals, was performed using miRNA-sequencing analysis. Results: The variation of exosomal miRNA expression between control group (NR) and NCSLC samples (AM and AW) was identified. 96 significantly different expressed miRNAs were identified. Of these, 39 miRNAs were upregulated and 57 were downregulated. 11 miRNAs were downregulated, and 31 miRNAs were upregulated in the miRNA expression between NR and AM. Compared with healthy donors, 54 upregulated miRNAs and 36 downregulated miRNAs were observed in samples from AW patients. 40 different expressed miRNAs were identified in AM samples, compared with AW. Ten of upregulated miRNAs are miR-260, miR-1169, miR-117, miR-15b-5p, miRNA-731, miR-342-5p, miR- 898, miR-1384, miR-56, and miR-1214. Ten of downregulated miRNAs are miR-99b-5p, miR-1116, miR-689, miR-818, miR-604, miR-72, miR-955, miR-403, miR-1228, and miR-836. Conclusion: The exosomal miR-1169 and miR-260 as potential candidates, which contain specific characteristics that can distinguish between wild-type EGFR and mutant EGFR NSCLC patients in early-stage cancers. © 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC